北京炫景瑞医药科技

Shine-On Pharma is a Beijing-based biotechnology company specializing in the discovery and development of next-generation small molecule therapeutics, with a primary focus on targeted protein degradation (TPD). The company leverages its proprietary platform to develop molecular glues and PROTACs (Proteolysis-Targeting Chimeras) for challenging targets in oncology and immunology. Founded by industry veterans with extensive experience in global drug discovery, Shine-On Pharma aims to address unmet medical needs by converting "undruggable" proteins into therapeutic opportunities. The company has successfully secured venture capital funding to advance its early-stage pipeline toward clinical development. Its research strategy emphasizes the precise modulation of protein levels to treat complex diseases such as solid tumors and hematological malignancies.